ATTN: As of June 9, our Harbour View office in Suffolk has relocated to 3910 Bridge Road, Ste. 400.  

2025 UPDATES: Please bring all new insurance cards to your next appointment and verify your address and phone number when you check in at the front desk. 

Clinical Research & Trials

USO 24326

A PHASE 1B, MULTICENTER, OPEN-LABEL STUDY OF THE SAFETY AND EFFICACY OF CHS-114 IN COMBINATION WITH TORIPALIMAB WITH OR WITHOUT OTHER TREATMENTS IN PARTICIPANTS WITH ADVANCED OR METASTATIC SOLID TUMORS (CHS-114-102)

 

Disease Types: Gastrointestinal Cancer Research

Eligibility Requirements:

• Histologically or cytologically confirmed unresectable,
locally advanced or metastatic gastric or GEJ cancer
• Must be HER2-negative and MSS/pMMR
• Subject must have progressed during or after 1L therapy
that includes a platinum and fluoropyrimidine doublet with
or without anti-PD-1/PD-L1–directed therapy
• Subjects must provide a tumor tissue sample
• Subjects with prior exposure to an anti-CCR8 antibody are
excluded
• Subjects that have received ≥ 2 prior systemic anticancer
therapies for advanced or metastatic disease

For more information on this trial CLICK HERE .

Available at: